Mount Sinai Builds Supercomputer for Precision Medicine, Genomics

HealthITAnalytics | November 19, 2019

Mount Sinai Health System has received a $2 million grant from the US Department of Health and Human Services to develop a precision medicine and genomics supercomputer. The second “big omics data engine” (BODE 2) will enable Mount Sinai researchers to explore complex scientific questions more quickly and accelerate new solutions for a wide range of medical disorders. Supercomputers have become essential in biomedical scientific discovery, and Mount Sinai has been a leader on this front, making investments in computational and data science that are advancing our understanding of and ability to treat complex diseases,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System.

Spotlight

This video describes when a Veteran should seek emergency care and provides general information about when and how VA can pay for a Veteran's service-connected and non-service connected emergency care.


Other News
MEDICAL DEVICES

Medtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System

Medtronic | January 11, 2022

Medtronic plc, a global leader in healthcare technology,today announced it has received approval fromJapan'sMinistry of Health, Labor and Welfare for the sale and reimbursement of the Micra™ AV Transcatheter Pacing System (TPS), and the company will launch the product this month. This approval expands the number of patients inJapan– one of the largest markets in the world – who are eligible to receive the Micra TPS, the world's smallest pacemaker. The Micra AV is indicated for the treatment of patients with AV block, a condition in which the electrical signals between the chambers of the heart (the atria and the ventricle) are impaired. The Micra TPS is the first-ever leadless pacemaker; its first version (the Micra VR) was approved inJapanin 2017 for patients who only require single-chamber pacing. "Pacemakers have made significant progress over their approximately 60-year history, including miniaturization, improvements in pacing technology, MRI compatibility, and remote monitoring," explainedKyoko Soejima, professor of cardiovascular internal medicine at Kyorin University Hospital and a member of the Micra TPS Global Clinical Trial steering committee. "The first Micra system transformed the concept of pacemakers by eliminating surgical pockets and leads, and Micra AV promises to deliver the benefits of leadless pacing to a larger number of patients because ventricular pacing can be performed synchronously with the atrium." Historically, patients with AV block have been treated with traditional dual-chamber pacemakers which are implanted in the upper chest, under the skin below the collar bone, and connected to the heart using thin wires called "leads." Identical in size and shape to the original Micra TPS, Micra AV has several additional algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providing "AV synchronous" pacing therapy to patients with AV block. The Micra AV approval is based on data from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study, which evaluated the safety and effectiveness of accelerometer-based atrial sensing algorithms. The study evaluated the ability of the Micra's internal sensor to monitor and detect atrial contractions and enable coordinated pacing between the atrium and ventricle, thereby providing AV synchrony. "Since introducing the first battery-powered external pacemaker in 1957 to the innovative Micra leadless pacemaker portfolio, Medtronic continues to pioneer pacing innovations for physicians and their patients." Rob Kowal, M.D., Ph.D., chief medical officer of the Cardiac Rhythm Management business at Medtronic About the Micra Transcatheter Pacing Systems (TPS) The Micra TPS received CE Mark inApril 2015and U.S. FDA approval in 2016. Comparable in size to a large vitamin, Micra is less than one-tenth the size of traditional pacemakers yet delivers advanced pacing technology to patients via a minimally invasive approach. During the implant procedure, the device is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device. Unlike traditional pacemakers, Micra does not require leads or a surgical "pocket" under the skin, so potential sources of complications related to leads and pockets are reduced, and there is no visible sign of the device. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered inDublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Read More

FUTURE OF HEALTHCARE

SpineGuard Announces a New Partnership with Sorbonne, CNRS and Inserm to associate its DSG® Technology With Ultrasound and Serve Surgical Robots

SpineGuard | June 08, 2022

pineGuard an innovative company that deploys its DSG sensing technology to secure and streamline the placement of bone implants, announces the launch of a new three-year collaboration program with two labs of Sorbonne University CNRS and Inserm: the ISIR. DSG is based on the local measurement of electrical conductivity of tissues in real time without X-ray imaging, with a sensor located at the tip of the drilling instrument. Its efficacy was proven by more than 90,000 surgeries across the globe and 19 scientific publications. SpineGuard has entered in 2017 a collaboration with ISIR for the application of DSG to surgical robots and the enhancement of their safety, accuracy, and autonomy. SpineGuard and ISIR capitalize on first order outcomes published so far… At the close of a first collaboration phase, SpineGuard announced sub-millimetric accuracy experimental outcomes in bone boundary detection and automatic stop of a vertebral drilling performed by a robot using the DSG technology. These impressive outcomes were presented as they were produced successively at the Hamlyn medical robotics conference in London in May 2019, receiving the first price for best scientific paper, then in plenary session at the SMISS minimally invasive spine surgery (SMISS) in Las Vegas in November 2021, and lastly during the CRAS conference in Naples in April 2022. … and join forces with the LIB laboratory in order to add ultrasound to the project. Encouraged by this success, the research and development teams wish to go even further in surgical robots advancement: the guidance technologies that allow the robot to position itself properly relative to the patient to find the drilling entry point rely today on X-Ray imaging, dangerous for health, in combination with space-consuming optical registration. SpineGuard has long explored the possibility to use ultrasound complementarily to DSG for this preliminary step, before the tool is penetrating bone, and was granted two families of international patents on that topic. The LIB laboratory, who features an international level expertise in the field of ultrasound imaging, answered with enthusiasm the invitation to join the project. SpineGuard, ISIR and LIB thus start a new 3-year collaboration that is expected to produce breakthrough results in the field. “We are happy to launch this partnership that will allow us to go even further in improving surgical robots in orthopedics. This new phase of the project aims at enabling robots to perform bone drilling and cutting, as well as implant placement, in a secured and more autonomous manner in the human skeleton. Our goal is to implement first-class collaboration between French Research and Industry and trigger commercial ventures in the orthopedic field via strategic agreements with industry partners.” Stéphane Bette, co-founder and Deputy CEO of SpineGuard Guillaume Morel, Professor at Sorbonne University and ISIR Director, and Brahim Tamadazte, Researcher at CNRS and member of ISIR, added: “We are delighted to continue the close and dynamic collaboration initiated in 2017 with SpineGuard. The entry of robotics and associated new technologies in operating room is no doubt one of the biggest medical advances of the last twenty years. Robotic approaches often allow the surgical gesture to be less invasive, more accurate, safe and intuitive in numerous surgical procedures. The first outcomes from the previous collaboration gave us more visibility on the clinical added value that a robot with original and effective sensors can bring to Orthopedic Surgery in general and Spine in particular. This new collaboration will be about ultrasonic sensors coupled with robotics. This original and promising association will allow the surgeon to define the entry point and the pedicle screw trajectory accurately and non-invasively, without relying on ionizing or costly preoperative imaging (scanner, MRI). The association of two prestigious labs of Sorbonne University (ISIR and LIB), whose competencies are highly complementary to SpineGuard’s industrial vision constitute a stimulating work environment favorable to innovation. The journey with SpineGuard goes on for three more years with a target of several technologic and scientific innovations to serve patients and care providers.” Quentin Grimal, Professor at Sorbonne University and Manager of the team “Ultrasound and imaging for bone quality characterization” at LIB, concludes: “Using ultrasound to position a surgical tool is particularly relevant. Ultrasounds are danger free and provide real time information about interfaces, bone anatomy, even bone mechanical quality. The use of an ultrasound probe should allow to position the robotic arm in an optimal manner to place pedicle screws. In general, echography does not allow to see beyond the bone surfaces because ultrasounds are strongly reflected at the surface and strongly attenuated when propagating in bone. Low amplitude signals coming from inside bone can however be exploited through specific treatments which are a specialty of our team. Our team, pioneer in ultrasound utilization to probe bone, has introduced several approaches that offer an alternative to X-Rays for characterization of trabecular or cortical bone health. For our team, this partnership with SpineGuard and ISIR is a great fit: it will accelerate methodology and instrument developments for a broader utilization of ultrasound in orthopedic surgery. We are very happy to participate in this innovation rich project.” About SpineGuard® Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 90,000 surgical procedures worldwide. Nineteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard has expanded the scope of its DSG® technology in innovative applications such as the « smart » pedicle screw, the DSG Connect visualization and registration interface, dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives. About ISIR ISIR is one of the largest French Research institutions in robotics and intelligent systems, reporting mainly to Sorbonne University, CNRS (National Center for Scientific Research) and Inserm (National institute for health and medical research). It regroups more than 50 teaching researchers and permanent researchers and approximately 80 PhD ad post-doc students. ISIR is structured around 6 research teams focused on artificial intelligence and machine learning, mobile robotics, small scale robotics, assistance robotics (physical therapy and mobility support), human-robot interaction and surgical gesture assistance. ISIR has a rich expertise in the design of innovative robotic architectures, simulation and control, clinical validation and transfer of high industrial potential results. Over the last 5 past years, 10 pre-clinical or clinical studies were conducted at ISIR. 8 patents were granted, and 2 start-up companies created. About LIB The Laboratory for biomedical imaging (LIB) is specialized in Fundamental and Applied Research for biomedical morphologic imaging methods, functional and molecular on small animal and human. It reports to Sorbonne University, CNRS and INSERM. It regroups 35 permanent researchers and teaching researchers, of whom half are also hospital practitioners, approximately 10 engineers and technicians and more than 30 PhD students and post-docs. LIB is structured around 6 teams whose focuses correspond to key priorities of 21st century Public Health: cancer, cardiovascular and neurologic diseases, bone quality. LIB develops new diagnostic and treatments methods exploiting various modalities: ultrasound, MRI, CT, SPECT-PET, etc. LIB has a strong commitment to technology transfer. Over the last 5 years, 6 patents were granted, 7 software were filed, and 5 startup companies launched.

Read More

FUTURE OF HEALTHCARE

TRC Healthcare Expands Portfolio with the Acquisition of QURE Healthcare

TRC Healthcare | March 16, 2022

TRC Healthcare a trusted leader in continuing education, has acquired QURE Healthcare, a recognized innovator in clinical measurement and quality improvement. QURE's provider-focused solutions lead to better patient outcomes and lower costs for healthcare systems and coverage and reimbursement for life-science clients. TRC's acquisition paves the way for QURE to scale its innovative Clinical Performance and Value (CPV®) patient simulation software solutions. "Through the acquisition, TRC Healthcare intends to augment its already robust suite of products by focusing on improving patient outcomes with evidence-based training, education and continuing education/continuing medical education for physicians and other providers" TRC Healthcare's CEO,Wes Crews, announced. "QURE is excited to join a company that is so aligned with our mission to raise the quality of healthcare, standardize practice and lower costs by changing clinician behavior. Measuring and reducing care variation using CPV®vignettes is QURE's core business. We have demonstrated in the peer-review literature that we can do this from the ambulatory to the intensive care setting and for diseases ranging from angina to zoonoses, all with the goal to eliminate unwarranted variation, raise quality for patients and lower costs for payers." Dr.John Peabody, the founder and president of QURE TRC Healthcare regards QURE as another key addition to its recent acquisition of NetCE, an industry leading continuing education platform that educates nurses, physicians, and mental health professionals. Together, QURE and NetCE fortify the evidence-based healthcare solutions TRC offers, "The addition of QURE increases our link between strong education and better patient outcomes," remarkedWes Crews. Dr. Peabody will continue to serve as QURE's President and will take on the additional role of Chief Medical Officer at TRC Healthcare. Dr. Peabody is a renowned international health care figure in clinical care quality and a professor at theUniversity of California, San FranciscoandLos Angeles. In 2012, John started QURE Healthcare. The QURE platform – CPV® vignettes – has grown and become a widely adopted standard for measuring clinical practice. QURE CPVs are used by organizations looking to engage their providers in clinical variation reduction efforts, including large health care systems, independent practice associations, public and private payers, governments, non-governmental associations, and intergovernmental organizations. Dr. Peabody has contributed more than 200 articles, books, and abstracts to the peer-review literature, served on blue ribbon committees, testified before congress and advised heads of state on a wide variety of subjects notably quality improvement and the economic benefits of standardizing practice in healthcare systems. "QURE is an extraordinary company, with a validated product and team and an incredibly passionate community of users," saidWes Crews. "Together we can transform the way we engage providers and change patient care." About TRC Healthcare TRC Healthcare (TRC) is a premier source of lifelong learning solutions for healthcare professionals. TRC is most recognized for their education and CE offerings within the highly-regarded Pharmacist's Letter, Prescriber's Letter, and Pharmacy Technician's Letter. TRC also offers Pharmacy Technicians University, the leading online training program for pharmacy technicians. The Natural Medicines database makes it easy for subscribers to find unbiased, evidenced-based research about alternative drug therapies. Through the acquisition of CriticalPoint, NetCE and Bula TRC Healthcare has been expanding its offerings. CriticalPoint increases patient safety through a variety of educational compounding offerings concentrating on USP 797, 800, and 795. NetCE is an industry-leading, continuing- education platform supporting multiple professions including nurses, physicians, and mental health. And Bula provides legal and regulatory advice to retail pharmacies. These additions give TRC Healthcare the industry's largest catalog of continuing education and advisory services, with thousands of courses trusted by healthcare professionals to provide accredited training that meets continuing education and licensing requirements. About QURE QURE Healthcare is a provider engagement company committed to improving the quality of clinical care. using its proprietary technology, CPV®(Clinical Performance and Value) vignettes. CPV®vignettes

Read More

FUTURE OF HEALTHCARE

Laborie Medical Technologies Acquires GI Supply

Laborie Medical Technologies | April 21, 2022

Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp. announced that it has completed the acquisition of GI Supply, a leader in specialty endoscopy and paracentesis products for gastroenterologists, colorectal surgeons, and interventional radiologists. As part of the transaction, GI Supply and all its employees will be fully integrated into the Laborie business. "We've had the opportunity to work closely with the GI Supply team for two years and are delighted to welcome them into the Laborie family," said Michael Frazzette, President & CEO of Laborie Medical Technologies. "We look forward to working together in our mission to deliver innovative technologies that help preserve and restore human dignity. Gastroenterology will continue to be a core segment for Laborie and legacy GI Supply will lead our effort." In 2020, Laborie and Signet Healthcare Partners, a healthcare growth equity firm, signed an agreement to acquire GI Supply. The combined GI Supply and Laborie product portfolio and commercial capabilities enabled the organizations to reach a larger customer base and offer healthcare practitioners a broad portfolio of innovative gastroenterology products. "We are delighted with the growth and progress of GI Supply over the past several years. We thank Patricia Industries and Laborie for their partnership in helping to develop this business. The future is very bright for GI Supply as part of Laborie." Ashley Friedman, Managing Director at Signet Healthcare Partners Yuriy Prilutskiy, Head of North America at Patricia Industries, a part of Investor AB and majority owner of Laborie Medical Technologies added, "Patricia Industries is excited to continue investing in Laborie's long-term growth with this acquisition. We continue to support Laborie in its mission to provide patients and healthcare professionals with innovative and effective therapeutic and diagnostic technologies that preserve and restore human dignity." About Laborie Medical Technologies Headquartered in Portsmouth, New Hampshire, Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. We manufacture and deliver high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Clinicians and hospitals look to us as the market-leading experts in our business segments, and we support our products with a world-class Clinical Education & Information program. Laborie is a portfolio company of Patricia Industries. About GI Supply As a physician-founded company, we strive for deep clinical input into all that we do. GI Supply is broadening its portfolio with solutions that allow physicians to perform more-advanced procedures safely and efficiently. We help doctors do their jobs faster, safer and simpler. About Patricia Industries Patricia Industries, a part of Investor AB, invests in best-in-class companies with strong market positions, brands and corporate cultures within industries positioned for secular growth. We invest with an indefinite holding period and partner with great management teams to create value for people and society by building strong and sustainable businesses. About Investor AB Investor, founded by the Wallenberg family in 1916, is an engaged owner of high-quality, global companies. We have a long-term investment perspective. Through our board participation, industrial experience, global network and financial strength, we work continuously to support our companies to remain or become best-in-class. About Signet Healthcare Partners Signet Healthcare Partners is an established provider of growth capital to innovative healthcare companies. Signet invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm invests primarily in pharmaceutical and medical device companies. As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet's 24-year history, the firm has developed a strong reputation and track record of successful healthcare investments. Signet has raised funds with total capital commitments of over $500 million and has invested in more than 55 companies.

Read More

Spotlight

This video describes when a Veteran should seek emergency care and provides general information about when and how VA can pay for a Veteran's service-connected and non-service connected emergency care.

Resources